Abstract: A method for treatment of prophylaxis of a chronic disease or condition associated with impaired tissue or organ perfusion, comprising administering an amino-C2-C6-alkyl nitrate, an amino-C2-C4-alkyl nitrate, or a pharmaceutically acceptable salt thereof, to a patient in need thereof. The disease or condition is a micro- and/or macro-vascular disease selected from the group of diseases associated with impaired capillary function, impaired muscular function, impaired skin function, impaired cartilage function, impaired myocardial function, impaired retinal function or impaired organ function caused by impairment of tissue and organ perfusion or by impairment of the regeneration of capillaries, arterioles or other vascular tissue. Examples of such diseases are diseases associated with impaired wound healing (including burning injuries), ulcers (e.g.

Abstract: The present invention relates to extended release compositions of an amino-C2-C6-alkyl nitrate and of pharmaceutically acceptable salt thereof, in particular 2-aminoethyl nitrate, and to fixed dose combinations with further pharmaceutically active drug substances. 2-Aminoethyl nitrate does not provoke nitrate tolerance, but has a very short half life in physiological systems.

Abstract: The present invention relates to extended release compositions of an amino-C2-C6-alkyl nitrate and of pharmaceutically acceptable salt thereof, in particular 2-aminoethyl nitrate, and to fixed dose combinations with further pharmaceutically active drug substances. 2-Aminoethyl nitrate does not provoke nitrate tolerance, but has a very short half life in physiological systems.

Abstract: The present invention relates to extended release compositions of an amino-C2-C6-alkyl nitrate and of pharmaceutically acceptable salt thereof, in particular 2-aminoethyl nitrate, and to fixed dose combinations with further pharmaceutically active drug substances. 2-Aminoethyl nitrate does not provoke nitrate tolerance, but has a very short half life in physiological systems.

Abstract: A process for the preparation of color-stable levulinic acid by saponification of acetylsuccinates with aqueous mineral acids, by continuously treating the starting products with steam in counter-current in a reactor cascade, the reaction being carried out above the boiling point of the alcohol being formed in the reaction or above the boiling point of the aqueous azeotrope being formed.

Abstract: Process for the preparation of pure 1-phenyl-3-carbalkoxy-5-hydroxypyrazoles of the general formula ##STR1## in which R denotes methyl or ethyl, by reaction of acetylsuccinic esters with phenyldiazonium chloride and a base with pK.sub.B value of 3.6 to -1.5 at a pH of 4 to 9 in an aqueous medium to give the corresponding phenylhydrazone, which is cyclized at a pH of 7 to 9.5, with warming and with the addition of ammonia, to give the ammonium salt of the hydroxypyrazole. Compound I is formed by acidification.